About 1 in 5 women will experience depression and anxiety during pregnancy or in the year after giving birth. If untreated, a mother who has these conditions has a higher risk of birth complications, overall poorer health, impaired bonding and nurturing of her infant, and a higher risk of death by suicide.
But a new treatment moving through the Food and Drug Administration clinical trials process may be key to treating, or even curing, depression and anxiety in postpartum people. It is a newly named psychedelic, luvesilocin. It functions like psilocin, the psychoactive chemical within psilocybin mushrooms. It may be able to positively affect the unique hormonal shifts, brain changes and disconnection that can lead to these conditions like no existing treatments.
In prior studies of psilocybin, researchers have observed rapid improvement in symptoms – and sometimes a cure after a single dose – of conditions such as major depression and PTSD. In a recent FDA Phase 2 study of luvesilocin, we found similar improvements in postpartum depression.
I was the site investigator for the University of Colorado, one of 35 participating sites across the U.S. The study enrolled 84 postpartum women who were within a year of giving birth and ended in May 2025.
I have spent my career as a board-certified obstetrician-gynecologist contemplating how the prenatal experience shapes lifetime health. I have also followed the psychedelic data closely. I’ve been eager to find evidence-based pregnancy and postpartum applications of psychedelics, given these drugs’ promise in treating other mental health conditions.
Depression and anxiety’s impact on moms and babies
One drug that has been studied and enhanced our understanding of the way psychedelics work is MDMA, which is commonly known as ecstasy and causes a euphoric high.
According to peer-reviewed research published by Bessel van der Kolk in 2024, MDMA can lead to improvements in individuals being able to identify, describe and feel their feelings. Other improvements resulting from MDMA assisted therapy include more self-compassion and a broader desire and capacity for connection with others.
Connection, especially the earliest one between a mother and infant, plays one of the most significant roles in providing the foundation for humans to grow and flourish. Postpartum depression is often defined by disconnection and impaired bonding.
Children born to mothers with untreated depression and anxiety have a higher risk of falling behind on early developmental milestones. They may also have behavioral concerns, such as hyperactivity or ADHD, and are more likely to withdraw from social activities. They tend to report somatic complaints, such as body aches and pains in early childhood.
Children of mothers who had depression or anxiety during pregnancy are also at risk of these same conditions as they enter their teenage years. They have nearly twice the risk of these conditions compared to teenagers whose mothers did not have untreated depression and anxiety. This pattern means depression and anxiety can become a multigenerational cycle. But this cycle can be interrupted with adequate treatment and support.
Increased levels of the hormone oxytocin were found by researchers in the blood of depression study participants who were given MDMA, LSD and mescaline, which are all psychedelic drugs. The increase in oxytocin led to more feelings of trust, empathy and connection.
Oxytocin is a hormone produced in the part of the brain called the hypothalamus and is released from the pituitary gland into the bloodstream. It plays a critical role in birth and infant feeding. It also aids in the wiring and formation of human social brains.
Oxytocin is important in maternal bonding with an infant. Conversely, early childhood stressors, such as a mother suffering from mental illness, reduces oxytocin levels in children. This may be a contributor to adverse mental and physical health outcomes later in life.
In depression studies that involved men, psilocybin did not have as great of an impact as other psychedelic medications on oxytocin production. But there is reason to believe that oxytocin may play a greater role in postpartum patients because it’s levels are higher during birth and lactation than in other phases of life.
FDA study of psilocybin-like medication
In February 2026, the FDA granted luvesilocin breakthrough therapy status. This status is used to speed up the development of promising new medications for serious or life-threatening conditions. The drug received this status because our research found meaningful and rapid reductions in depression scores in those who received the treatment.
In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.
The purpose of an FDA Phase 2 study is to determine the effectiveness of an experimental medication on a particular disease or condition. In this case, the study is evaluating luvesilocin’s effect on postpartum depression scores and symptoms. In the group that received the placebo, a microdose of the drug, more than half experienced an improvement in their symptoms, but most still had some symptoms after seven days.
These are much higher response and remission rates than trials of the existing medications used for postpartum depression treatment. Existing treatments include selective serotonin reuptake inhibitors, known as SSRIs, and a medication called zuranolone. The latter is the only medication to have specific FDA approval for postpartum depression.
Access to psychedelic treatments
In 2023, the Colorado legislature passed the Natural Medicine Health Act. It offers a legal pathway for people to receive natural psychedelics, such as psilocybin mushrooms, in therapeutic settings. The first natural medicine healing centers opened in early 2026. Some locations advertise treatments for everything from postpartum depression to birth trauma.
Oregon has a similar state-regulated program. Numerous other states have different pathways toward legal psychedelic-assisted therapies and decriminalization of psilocybin-assisted therapy. Nationally, there was a recent federal executive order to accelerate action on treating serious mental illnesses. The order included mention of the use of psychedelic therapies.
Looking forward
By the end of 2026, Phase 3 of the luvesilocin trial for postpartum depression is slated to begin. Phase 3 trials are conducted to confirm the effectiveness and further evaluate the overall risks and benefits of a new medication. Each phase is an important regulatory step before a medication can be approved and available in clinical settings.
In Phase 3, 200 participants with postpartum depression will be recruited across participating sites. While I’m optimistic about the potential of this research, I believe its value can be established only through rigorous blinded clinical trials, objective data analysis, and conclusions and approval that are fully supported by the evidence.
Phase 3 will also include participants who are still breastfeeding. A study of luvesilocin during lactation in healthy volunteers demonstrated very low levels passed from the mother into breast milk. Thus, this medication would be considered safe for breastfeeding.
Luvesilocin may become a game-changing postpartum depression treatment medication in just a couple more years. On a much larger scale, psychedelic medicine could elevate our collective well-being and happiness, replacing systemic cycles of depression, anxiety, trauma and isolation with connectedness and compassion. These drugs could literally rewire our approach to trauma, addiction and how we relate to one another.
This article is republished from The Conversation under a Creative Commons license. Read the original article.